Accession Number:

AD1159619

Title:

Prostate Cancer Clinical Trials Consortium Clinical Research Site: University of Washington

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

WASHINGTON UNIV SEATTLE

Personal Author(s):

Report Date:

2021-10-01

Pagination or Media Count:

251

Abstract:

Participate as an active and productive member of the Prostate Cancer Clinical Trial Consortium PCCTC throughout the funding period. The PCCTC provides a mechanism for participation in early clinical development of novel agents and rapid testing of these agents for the treatment of prostate cancer. Many of the PCCTC trials have challenging entry criteria such as a biopsy of metastatic tissue or complicated pharmacokineticspharmacodynamics, and collection of correlative biomarkers. The PCCTC is well positioned to conduct such trials that might not be possible outside of sites that specialize in prostate cancer translational research. Shortening drug development time with better trial design, patient selection, and validation of biomarkers will bring new agents to prostate cancer patients faster, optimize treatment for the individual patient, and avoid treating others with ineffective therapies.

Descriptors:

Subject Categories:

  • Medicine and Medical Research
  • Anatomy and Physiology

Distribution Statement:

[A, Approved For Public Release]